18 Years and older

Scalp psoriasis amenable to topical treatment with a maximum of 100 g of study medication per week

Clinical signs of psoriasis vulgaris on trunk and/or limbs, or earlier diagnosed with psoriasis vulgaris on trunk and/or limbs

Extent of scalp psoriasis involving more than 10% of the total scalp area

Disease severity on the scalp graded as Moderate, Severe or Very Severe according to the Investigator's Global Assessment of disease severity

PUVA or Grenz ray therapy anywhere on the patient within 28 days prior to randomisation

UVB therapy anywhere on the patient within 14 days prior to randomisation

Systemic use of biological treatments, whether marketed or not, directed against or with a potential effect on, scalp psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab) within 6 months prior to randomisaiton

Systemic treatments with a potential effect on scalp psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within 28 days prior to randomisation

Any topical treatment for scalp psoriasis or any other skin disease on the scalp (excluding medicated shampoos, emollients and hair conditioners) within 14 days prior to randomisaiton

Topical treatment for other skin disorders with very potent WHO group IV corticosteroids within 14 days prior to randomisation

Planned initiation of, or changes in dose of concomitant medication that could affect scalp psoriasis (e.g., beta blockers, antimalarial drugs, lithium) during the study

Current diagnosis of guttate, pustular, exfoliative or erythrodermic psoriasis

Patients with any of the following conditions present on the scalp area: viral lesions, fungal and bacterial skin infections, parasitic infections and atrophic skin

Known or suspected severe renal insufficiency or severe hepatic disorders

Patiens with history/signs/symptoms suggestive of an abnormality of calcium homeostasis associated with clinically significant hypercalcaemia

Trial subjects should be using an adequate method of contraception